Archive for the ‘Otonomy Inc’ Category

Otonomy

December 18th, 2015 | Posted in Otonomy Inc

Ontonomy‘s antibacterial drug, Otiprio, which was being tested to treat pediatric patients with a type of middle ear infection in children receiving ear tubes (tympanostomy tube placement surgery), has received approval from the DFA. Otonomy is now planning to get Otiprio on the market in earl 206.. The San Diego-based company will recruit a 40-person sales force […]

Otonomy Inc

September 5th, 2014 | Posted in 2014, Otonomy Inc

Shares of Otonomy Inc, San Diego, rose after the initial public offering raises more than $100 Million. The biotech develops treatments for ear diseases. Currently, the company is seeking regulatory approval for its antibiotic AuriPro.

Otonomy Inc

July 21st, 2014 | Posted in 2014, Otonomy Inc

Otonomy, Inc., San Diego, has filed with the SEC for an initial public offering of its common stock. The number and price range have yet to be determined. The company is a clinical-stage biopharmaceutical focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear.

Otonomy Inc

May 8th, 2014 | Posted in 2014, Otonomy Inc

San Diego-based Otonomy Inc has raised another $49 Million in a series D round of financing. The biopharmaceutical develops and commercializes therapeutics for diseases and disorders of the inner and middle ear.

Otonomy Inc

March 6th, 2014 | Posted in 2014, Otonomy Inc

Otonomy Inc. – San Diego:  is a clinical state biopharmaceutical company who recently appointed Robert Savel as Chief Technical Officer “CTO.”  The company is developing therapeutics for diseases and disorders of the inner and middle ear.

Otonomy Inc

February 18th, 2010 | Posted in Otonomy Inc

Otonomy Inc., San Diegok, has received regulatory clearance for its Investigational New Drug application for the clinical trial of OTO-104 in patients with Maniere’s disease.  Meniere’s disease is a disorder of the inner ear affecting balance and hearing.